Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28610687 | 0.86 | HDAC8 (0.48) | GAAALDH1A1KMT2AHPGDHSD17B10 | |
| SCHEMBL18190399 | 0.83 | P2RX7 (0.50) | GAAALDH1A1KMT2AHPGDHSD17B10 | |
| SCHEMBL1853517 | 0.82 | ALDH1A1 (0.66) | PLK1GAAALDH1A1KMT2AHPGD | |
| SCHEMBL30339452 | 0.80 | PLK1 (0.53) | PLK1GAAALDH1A1KMT2AHPGD | |
| SCHEMBL4155499 | 0.80 | PLK1 (0.53) | PLK1GAAALDH1A1KMT2AHPGD | |
| SCHEMBL11089840 | 0.79 | PRNP (0.47) | GAAALDH1A1KMT2AHPGDHSD17B10 | |
| SCHEMBL2062590 | 0.79 | PLK1 (0.49) | PLK1GAAALDH1A1KMT2AHPGD | |
| SCHEMBL145178 | 0.79 | GAA (0.56) | PLK1GAAALDH1A1KMT2AHPGD | |
| SCHEMBL14164188 | 0.78 | PLK1 (0.52) | PLK1GAAALDH1A1KMT2AHPGD | |
| SCHEMBL6469935 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KMT2AHPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680096-B2 | Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators | SANOFI-AVENTIS (FR) | 2014-03-25 | — | — | US | disclosed |
| EP-2507238-B1 | DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| EP-2507238-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011067544-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | NR4A3, NCOR1, NR4A2 | PLK1 4782/4885GAA 4872/4885ALDH1A1 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.